C4 Therapeutics, Inc. Other than Temporary Impairment Losses, Investments
C4 Therapeutics, Inc. (CCCC) reported Other than Temporary Impairment Losses, Investments of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfInvestments · last filed 2022-02-24
- C4 Therapeutics, Inc. other than temporary impairment losses, investments for the quarter ending 2021-12-31 was $0.00.
- C4 Therapeutics, Inc. other than temporary impairment losses, investments for the quarter ending 2021-09-30 was $0.00.
- C4 Therapeutics, Inc. other than temporary impairment losses, investments for the quarter ending 2021-06-30 was $0.00.
- C4 Therapeutics, Inc. other than temporary impairment losses, investments for the quarter ending 2021-03-31 was $0.00.
- C4 Therapeutics, Inc. other than temporary impairment losses, investments for fiscal 2021 was $0.00.
- C4 Therapeutics, Inc. other than temporary impairment losses, investments for fiscal 2020 was $0.00.
| Period end | Other than Temporary Impairment Losses, Investments 3 month | Other than Temporary Impairment Losses, Investments 6 month | Other than Temporary Impairment Losses, Investments 9 month | Other than Temporary Impairment Losses, Investments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |